Every 8-K that VAXART INC (VXRT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow VXRT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VXRT filings page.
Vaxart, Inc. (VXRT) reported that its Board of Directors approved two governance policies on September 3, 2026. A new Director Resignation Policy requires any director who receives more "withhold" votes than "for" votes in an uncontested election to promptly tender a written resignation after certification of the stockholder vote. The Nominating and Governance Committee must review the offer and recommend whether to accept or reject it, and the Board must act on that recommendation within 90 days of vote certification.
The Board also adopted a Director Stock Ownership Policy, setting a target ownership level for non-employee directors equal to two times the current annual cash retainer for Board service, excluding committee or other incremental fees. Compliance will be measured annually as of December 31 using a 90-day simple moving average of the Company’s common stock price, and includes directly and indirectly owned shares as well as service-based restricted stock and restricted stock units.
Vaxart, Inc. (VXRT) reports that its Board of Directors has created two new committees: a Clinical and Regulatory Affairs Committee and a Stockholder Engagement Committee. The new Clinical and Regulatory Affairs Committee will review and provide oversight and advice on Vaxart’s research, clinical, and regulatory programs on behalf of the Board, and consists of James B. Breitmeyer, M.D., Ph.D. (Chair) and David Wheadon, M.D.. The Stockholder Engagement Committee will oversee the advancement of the company’s relations with stockholders, and consists of W. Mark Watson (Interim Chair) and Steven Lo. Under a Cooperation Agreement dated July 1, 2026, Vaxart anticipates appointing a new director in the future to serve as Chair of the Stockholder Engagement Committee. Vaxart notes that its common stock is quoted on the OTCQX Best Market under the symbol VXRT and includes a standard forward-looking statements disclaimer regarding the anticipated new director appointment.
Vaxart, Inc. reported its business update and financial results for the quarter ended June 30, 2026. The company released topline data from a 400-person sentinel cohort in its Phase 2b COVID-19 trial, showing safety of its oral pill vaccine compared with an approved mRNA comparator. Topline efficacy and safety data from the approximately 5,000-participant main cohort are anticipated in the first half of 2027.
For the second quarter of 2026, Vaxart reported revenue of $27.2 million, compared with $39.7 million a year earlier, and a net loss of $13.5 million. Revenue for the first six months of 2026 was $66.4 million. Cash, cash equivalents and investments totaled $64.0 million as of June 30, 2026, giving the company a stated cash runway into the second quarter of 2027.
Vaxart plans a live stockholder fireside chat on August 7, 2026 at 4:30 p.m. ET, accessible via webcast in the investor section of its website, to address frequently asked stockholder questions and discuss these updates.
Vaxart, Inc., a Delaware corporation whose common stock is quoted on the OTCQX Best Market under the symbol VXRT, reported changes to the structure of its Board committees.
On July 27, 2026, the Board approved a reorganization of the Nominating and Governance Committee and the Compensation Committee, effective August 1, 2026. Kevin P. Finney was appointed chair of the Nominating and Governance Committee, which will also include David Wheadon, M.D. The Compensation Committee will be chaired by James B. Breitmeyer, M.D., Ph.D., with Elaine J. Heron, Ph.D. and W. Mark Watson serving as members.
Vaxart, Inc. reported the results of its 2026 annual meeting of stockholders held on July 16, 2026. Proxies representing approximately 45.7% of outstanding common shares constituted a quorum. Stockholders elected six directors to serve until the 2027 annual meeting and ratified the selection of WithumSmith+Brown, PC as independent registered public accounting firm for the year ending December 31, 2026. However, stockholders did not approve, on a non-binding, advisory basis, the compensation of the named executive officers, with 46,024,068 votes for, 51,842,781 against and 2,300,962 abstentions, plus 10,463,289 broker non-votes.
The company also described its focus as a clinical-stage biotechnology company developing oral recombinant pill vaccines, including a Phase 2b trial of its oral COVID-19 vaccine candidate supported in part by Project NextGen and the RRPV Consortium.
Vaxart, Inc. reported 12‑month topline safety data from the approximately 400‑participant sentinel safety cohort in its Phase 2b trial of an oral pill COVID‑19 vaccine versus an approved mRNA comparator. Participants received either Vaxart’s oral pill vaccine (201 people) or an mRNA vaccine (199 people) targeting the XBB strain of SARS‑CoV‑2.
No vaccine‑related serious adverse events or sustained Grade 3 or higher adverse events were observed in either arm over 12 months, supporting a favorable safety profile for both regimens in this cohort. The full study includes this sentinel cohort plus about 5,000 participants in a main cohort dosed with vaccines targeting the KP.2 strain, with complete data anticipated in 2027.
The program is supported by Project NextGen through BARDA, ASPR, HHS and NIAID under a Rapid Response Partnership Vehicle Consortium award valued at up to $344.8 million, helping fund development of Vaxart’s proprietary oral pill vaccine platform.
Vaxart, Inc. entered into a Cooperation Agreement with a stockholder group that resolves a proxy contest ahead of the 2026 Annual Meeting of Stockholders. The stockholder group has withdrawn its competing director nominations and its demand to inspect certain company books and records.
Vaxart and the group will work together in the 60- to 90-day period after the 2026 meeting to select a mutually agreed independent “New Director,” who will join the Board and the Nominating and Corporate Governance Committee and chair a new Stockholder Engagement Committee. The Board will also form a Clinical and Regulatory Affairs Committee, adopt director resignation and stock ownership policies, and refresh key committee leadership.
Management will meet with the stockholder group at least once per fiscal quarter to discuss financial and strategic matters based on public information. Vaxart will reimburse the group’s documented expenses up to $650,000. The agreement includes customary voting, standstill and non-disparagement provisions and runs through a termination date tied to nomination deadlines for the 2027 or potentially 2028 annual meetings.
Vaxart, Inc. entered into a new modification of its BARDA-funded Project NextGen contract, resetting total funding for its Phase 2b oral COVID‑19 pill vaccine trial to approximately $345 million, which is about $116 million lower than the prior modification after trial enrollment was cut roughly in half by a BARDA partial termination.
The revised amount includes about $68 million of firm fixed price funding, with the remainder reimbursing trial preparation and execution costs, and also releases roughly $29 million to complete the study and perform exploratory safety and efficacy analyses. Vaxart expects to report 12‑month data from a 400‑participant sentinel cohort in the coming weeks and from the 5,085‑participant main cohort in the first half of 2027.
Vaxart, Inc. has filed preliminary proxy materials and issued an open letter ahead its 2026 Annual Meeting of Stockholders scheduled for July 16, 2026. The company highlights clinical progress for its oral vaccine platform, including a fully enrolled Phase 2b COVID-19 trial with about 5,400 participants and key data expected through early 2027. Vaxart states it has extended its cash runway into the second quarter of 2027 after cost reductions and dilutive financings, aiming to reach upcoming clinical milestones. The letter urges shareholders to back the board’s six director nominees in a contested election against three dissident candidates and notes the CEO holds more than 2.5 million shares. Deadlines for shareholder proposals and certain proxy-related notices are set at May 29, 2026.
Vaxart, Inc. reported a strong turnaround for the first quarter of 2026, with revenue of $39.2 million and net income of $5.2 million, compared with a net loss a year earlier. The improvement reflects higher revenue while keeping operating expenses roughly flat.
The company ended March 31, 2026 with $61.0 million in cash, cash equivalents, and investments, which it expects to fund operations into the second quarter of 2027. Vaxart is running a BARDA‑supported Phase 2b COVID‑19 oral pill vaccine trial, with topline 12‑month safety and efficacy data from a 400‑person sentinel cohort anticipated in the second quarter of 2026 and primary data from a 5,000‑participant main cohort expected in early 2027.
Vaxart also scheduled a live stockholder fireside chat for May 8, 2026 to discuss these updates and answer investor questions.
Vaxart, Inc. appointed James B. Breitmeyer, M.D., Ph.D. to its Board of Directors, effective immediately, following a recommendation from the Nominating and Governance Committee. The Board determined that he meets its independence standards.
Dr. Breitmeyer brings over 35 years of biopharmaceutical experience, including leadership roles at Altay Therapeutics, Oncternal Therapeutics, Bavarian Nordic, Eli Lilly, Cadence Pharmaceuticals and others. He has led clinical programs resulting in eight FDA product approvals and multiple regulatory successes in the U.S., Europe and Japan, including vaccine-related work at Bavarian Nordic.
He will receive cash and equity compensation under Vaxart’s standard Non-Employee Director Compensation Program and has entered into the company’s standard indemnification agreement. A press release announcing his appointment was furnished as an exhibit and is not deemed filed for Exchange Act liability purposes.
Vaxart, Inc. disclosed a change in its facilities in South San Francisco. The company amended its Utah Avenue lease to add two additional suites totaling approximately 3,531 rentable square feet, beginning on May 14, 2026, with a 36‑month term.
Separately, a previously signed termination agreement will end Vaxart’s Harbor Way headquarters lease, which covers approximately 24,606 rentable square feet, effective May 15, 2026. Together, these steps shift the company’s leased footprint from its former Harbor Way headquarters toward additional space on Utah Avenue.
Vaxart, Inc. entered into a share purchase agreement with Lincoln Park Capital that allows Vaxart, at its discretion, to sell up to $25.0 million of common stock over a 24‑month period once a resale registration statement is effective.
Vaxart can direct Lincoln Park to buy up to 150,000 shares per trading day, with higher share caps at higher stock prices, subject to a $500,000 daily limit and pricing set at 97% of specified market prices. Vaxart will issue 447,067 commitment shares as consideration and the agreement limits Lincoln Park’s ownership to 4.99%, includes no warrants or participation rights, and prohibits Lincoln Park from short selling the stock.
Vaxart reported a strong turnaround for 2025, moving to profitability and highlighting progress in its oral vaccine pipeline. Revenue rose to $237.3 million from $28.7 million in 2024, driving net income of $16.3 million versus a prior-year net loss of $66.9 million. Earnings were $0.07 per basic and diluted share.
The company ended 2025 with cash, cash equivalents and investments of $63.8 million and stated it has runway into the second quarter of 2027. Vaxart highlighted a worldwide collaboration with Dynavax for its COVID-19 oral pill vaccine and expects topline data from a 400-person Phase 2b sentinel cohort in early Q2 2026, with full efficacy and safety readout from about 5,000 participants expected in the fourth quarter of 2026. The company also reported positive norovirus vaccine data in lactating women showing passive antibody transfer to infants.
Vaxart, Inc. disclosed that it has entered into a termination agreement with Britannia Pointe Grand Limited Partnership to end its headquarters lease at 170 Harbor Way, South San Francisco. The lease covers approximately 24,606 square feet and will now terminate effective May 15, 2026, instead of the original expiration date of March 31, 2029.
Vaxart will pay rent and reimbursable expenses through the termination date, but will not owe any termination fees or penalties. The change is part of the company’s ongoing efforts to identify cost reduction opportunities. Vaxart intends to relocate its headquarters and labs to one of its other offices in the South San Francisco area.
Vaxart, Inc. (VXRT) furnished an 8-K to announce it issued a press release with a business update and financial results for the quarter ended September 30, 2025. The company attached the release as Exhibit 99.1 and stated the information is being furnished, not filed, under the Exchange Act and Securities Act provisions.
Vaxart also noted its common stock trades exclusively on the OTCQX Best Market under the symbol VXRT. No specific financial figures are included in this report; details are contained in the press release referenced as Exhibit 99.1.
Vaxart (VXRT) signed an exclusive, worldwide license and collaboration with Dynavax for its investigational oral coronavirus vaccines, including its oral COVID‑19 candidate. Vaxart will complete its ongoing Phase 2b trial and an end‑of‑Phase 2 FDA meeting; after that, Dynavax may elect to assume further development.
Dynavax will pay $25 million upfront and purchase 11,111,111 Vaxart shares at $0.45 per share (about $5 million) under Vaxart’s shelf registration, with closing expected on or about November 6, 2025. If Dynavax elects to take over development, it will pay an additional $50 million.
Vaxart may receive up to $195 million in regulatory milestones, up to $425 million in net sales milestones, and tiered royalties in the low‑to‑mid teens on net sales for licensed indications. Vaxart retains its platform rights for all non‑coronavirus indications. If Dynavax does not elect to continue, the agreement will terminate.
On October 8, 2025, Vaxart, Inc. disclosed that BARDA (through ATI) issued a Follow-Up Notice narrowing the scope of a Project Agreement to exclude "Paused Work." The company said ongoing activities will continue for the approximately 5,000 participants already enrolled in the Trial and that Vaxart will continue to receive funding to evaluate those participants. Vaxart stated it believes the Trial data from enrolled participants could provide useful insights and a foundation of evidence to potentially advance its COVID program. The filing clarifies these changes are furnished and not "filed" under Section 18, and it includes standard forward-looking statement language about risks and uncertainties.
Vaxart, Inc. reports that Nasdaq has decided to delist its securities after the company failed to meet conditions previously set by a Nasdaq Hearings Panel. Those conditions required shareholder approval of a reverse stock split by September 5, 2025, completion of the reverse split by October 6, 2025, and proof that the company met Nasdaq’s minimum bid price requirement. Vaxart withdrew its reverse stock split proposal on September 18, 2025, which left these conditions unmet.
Nasdaq’s Office of the General Counsel sent a letter on September 19, 2025 stating that Vaxart’s securities will be delisted. Trading of Vaxart’s common stock on Nasdaq has already been suspended since the open of trading on July 8, 2025. The company’s common stock is currently quoted on the OTCQX® Best Market under the symbol VXRT, meaning its shares continue to trade but no longer on a national securities exchange.
Vaxart, Inc. informed investors that a previously adjourned special meeting of stockholders, originally convened on September 5, 2025 and reconvened for September 19, 2025, will not be reconvened because the company withdrew the listed proposal from stockholder consideration on September 18, 2025. The proposal had been included in a proxy statement filed on August 6, 2025 and the meeting was adjourned earlier to give stockholders additional time to vote. The filing states only the withdrawal decision and that the company will not reconvene the adjourned meeting; no additional rationale, future steps, or timing for any alternative actions were provided.